Company Description

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products.

The company’s lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

It is also involved in the medical scientific research and development activities, as well as operates investment firms.

The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024.

PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

PMGC Holdings Inc.

Country	United States
Founded	2020
IPO Date	Nov 21, 2023
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Graydon Bensler

Contact Details

Address: 120 Newport Center Drive, Suite 249 Newport Beach, California 92660 United States
Phone	866-445-4886
Website	pmgcholdings.com

Stock Details

Ticker Symbol	ELAB
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.00
CIK Code	0001840563
CUSIP Number	28622K104
ISIN Number	US28622K1043
Employer ID	85-1399981
SIC Code	2834

Key Executives

Name	Position
Graydon Bensler C.F.A.	Chief Executive Officer, Chief Financial Officer, Secretary and Director
Braeden William Lichti	Executive Chairman of the Board

Latest SEC Filings

Date	Type	Title
May 1, 2025	8-K	Current Report
Apr 24, 2025	8-K	Current Report
Apr 24, 2025	8-K	Current Report
Apr 24, 2025	424B5	Filing
Apr 17, 2025	8-K	Current Report
Apr 16, 2025	SCHEDULE 13G/A	Filing
Apr 10, 2025	EFFECT	Notice of Effectiveness
Apr 10, 2025	8-K	Current Report
Apr 8, 2025	8-K/A	[Amend] Current report
Apr 7, 2025	8-K	Current Report

View All SEC Filings